ATE292960T1 - Pharmazeutische zubereitung zur anwendung in der antiasthmatherapie - Google Patents

Pharmazeutische zubereitung zur anwendung in der antiasthmatherapie

Info

Publication number
ATE292960T1
ATE292960T1 AT99909667T AT99909667T ATE292960T1 AT E292960 T1 ATE292960 T1 AT E292960T1 AT 99909667 T AT99909667 T AT 99909667T AT 99909667 T AT99909667 T AT 99909667T AT E292960 T1 ATE292960 T1 AT E292960T1
Authority
AT
Austria
Prior art keywords
antiasthmtherapy
pharmaceutical preparation
pharmaceutical
preparation
Prior art date
Application number
AT99909667T
Other languages
English (en)
Inventor
Nipun Davar
Atul D Ayer
Paul M Hwang
Brenda J Pollock
Padmaja Shivanand
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of ATE292960T1 publication Critical patent/ATE292960T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99909667T 1998-03-06 1999-02-26 Pharmazeutische zubereitung zur anwendung in der antiasthmatherapie ATE292960T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7709198P 1998-03-06 1998-03-06
PCT/US1999/004350 WO1999044592A1 (en) 1998-03-06 1999-02-26 Anti-asthma therapy

Publications (1)

Publication Number Publication Date
ATE292960T1 true ATE292960T1 (de) 2005-04-15

Family

ID=22136018

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99909667T ATE292960T1 (de) 1998-03-06 1999-02-26 Pharmazeutische zubereitung zur anwendung in der antiasthmatherapie

Country Status (9)

Country Link
US (1) US6224907B1 (de)
EP (1) EP1059917B1 (de)
JP (1) JP2002505275A (de)
AR (1) AR018582A1 (de)
AT (1) ATE292960T1 (de)
AU (1) AU2882299A (de)
DE (1) DE69924710T2 (de)
ES (1) ES2237088T3 (de)
WO (1) WO1999044592A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
AU1188601A (en) * 1999-09-20 2001-04-24 Alza Corporation Process for lessening polymorphic conversion of a drug
KR100381834B1 (ko) * 2000-05-20 2003-04-26 이상득 용출성이 개선된 프란루카스트 고체분산체 조성물 및 그제조 방법
WO2002085296A2 (en) * 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
MY148466A (en) * 2001-10-26 2013-04-30 Merck Frosst Canada Ltd Granule formulation
TW200302748A (en) * 2002-02-01 2003-08-16 Pfizer Prod Inc Osmotic delivery system
US20030161882A1 (en) * 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
US7226422B2 (en) 2002-10-09 2007-06-05 Cardiac Pacemakers, Inc. Detection of congestion from monitoring patient response to a recumbent position
US7148248B2 (en) * 2002-11-29 2006-12-12 Masako Nozaki Method of treating or inhibiting the development of brain inflammation and sepsis
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
IL174758A (en) * 2003-10-10 2012-09-24 Synthon Bv Crystalline form of montelukast, pharmaceutical composition comprising it, process for the preparation thereof and uses thereof as a medicament
EP1711166A1 (de) * 2004-02-03 2006-10-18 Chemagis Ltd. Stabile amorphe formen von montelukast natrium
US7387610B2 (en) 2004-08-19 2008-06-17 Cardiac Pacemakers, Inc. Thoracic impedance detection with blood resistivity compensation
WO2006066780A1 (en) * 2004-12-22 2006-06-29 F. Hoffmann-La Roche Ag Combinations of valategrast and montelukast for treating asthma
US20080254114A1 (en) * 2005-03-03 2008-10-16 Elan Corporation Plc Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
US20070065374A1 (en) * 2005-03-16 2007-03-22 Elan Pharma International Limited Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations
US7603170B2 (en) * 2005-04-26 2009-10-13 Cardiac Pacemakers, Inc. Calibration of impedance monitoring of respiratory volumes using thoracic D.C. impedance
US9089275B2 (en) * 2005-05-11 2015-07-28 Cardiac Pacemakers, Inc. Sensitivity and specificity of pulmonary edema detection when using transthoracic impedance
US7907997B2 (en) 2005-05-11 2011-03-15 Cardiac Pacemakers, Inc. Enhancements to the detection of pulmonary edema when using transthoracic impedance
JP4870402B2 (ja) * 2005-09-01 2012-02-08 小林化工株式会社 プランルカスト水和物含有錠の製造方法
US20070110802A1 (en) * 2005-11-15 2007-05-17 Janan Jona Wet granulation process
WO2007059325A2 (en) * 2005-11-16 2007-05-24 Teva Pharmaceutical Industries Ltd. Drying methods of montelukast sodium by azeotropic removal of the solvent
AU2006337648A1 (en) * 2006-02-09 2007-08-16 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulations of montelukast sodium
US20090012146A1 (en) * 2007-07-02 2009-01-08 Giridhar Reddy Buggana Solubility-enhanced pharmaceutical compositions comprising zafirlukast
US8093253B2 (en) * 2008-03-06 2012-01-10 Hoffmann-La Roche Inc. Leukotriene B4 inhibitors
CN101543480A (zh) * 2008-03-28 2009-09-30 兴和株式会社 片剂
JP2013540464A (ja) 2010-08-30 2013-11-07 サイナシス コーポレーション 副鼻腔開口部を拡張するため、および副鼻腔炎を治療するためのデバイスおよび方法
EP2819740A4 (de) 2012-02-29 2015-11-25 Sinusys Corp Vorrichtungen und verfahren zur dilatation einer paranasalen sinusöffnung und zur behandlung von sinusitis
US9687263B2 (en) 2013-05-30 2017-06-27 SinuSys Corporation Devices and methods for inserting a sinus dilator
PT109030B (pt) * 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL100091A (en) 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
EP0641569A4 (de) 1992-03-12 1997-01-29 Ono Pharmaceutical Co Antipruritisches agens.
DE69425453T2 (de) * 1993-04-23 2001-04-12 Novartis Ag, Basel Wirkstoffabgabevorrichtung mit gesteuerter Freigabe
AU6786794A (en) * 1993-05-10 1994-12-12 Sepracor, Inc. Methods and compositions using optically pure (+)-zileuton
US5529787A (en) * 1994-07-07 1996-06-25 Alza Corporation Hydromorphone therapy
WO1997006787A2 (en) 1995-08-17 1997-02-27 Dyer, Alison, Margaret Controlled release products

Also Published As

Publication number Publication date
DE69924710T2 (de) 2005-09-15
HK1033278A1 (en) 2001-08-24
EP1059917B1 (de) 2005-04-13
DE69924710D1 (de) 2005-05-19
EP1059917A1 (de) 2000-12-20
AU2882299A (en) 1999-09-20
US6224907B1 (en) 2001-05-01
ES2237088T3 (es) 2005-07-16
AR018582A1 (es) 2001-11-28
WO1999044592A1 (en) 1999-09-10
JP2002505275A (ja) 2002-02-19

Similar Documents

Publication Publication Date Title
ATE292960T1 (de) Pharmazeutische zubereitung zur anwendung in der antiasthmatherapie
DE60106623D1 (de) Neue pharmazeutische zusammensetzung
ATA1292000A (de) Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
ATE355271T1 (de) Pharmazeutische zusammensetzung
DE69916922D1 (de) Ibuprofenhaltige Arzneizubereitung
DE69925639D1 (de) Glicazidhaltige matrixtablette mit verzögerter wirkstoffverabreichung zur oralen anwendung
DE59915033D1 (de) Pharmazeutische Zubereitung
EE200300145A (et) Asa- ja polüasanaftalenüülkarboksamiidid ja farmatseutiline kompositsioon
ATE404180T1 (de) Geschmacksmaskierte pharmazeutische partikel
DE69726015D1 (de) Pharmazeutische zusammensetzung enthaltend koenzym q-10
CY2012033I1 (el) Φαρμακευτικα σκευασματα σε μορφη αερολυματος
DE69525148D1 (de) Pharmazeutische formulierung
DE59712959D1 (de) Orale pharmazeutische zubereitung enthaltend ibandronat
EE200000723A (et) Asendatud indolinoonid, nende valmistamine ja nende kasutamine ravimitena
DE60118859D1 (de) Pharmazeutische Zusammensetzung enthaltend Trehalose zur ophthalmischen Verwendung
DE60015279D1 (de) Stabilisierte pharmazeutische zusammentsetzung in lyophilisierter form
DE69827357D1 (de) Menschliches Wachstumshormon enthaltende pharmazeutische Zusammensetzung
DE60037816D1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
ATE257700T1 (de) Pharmazeutische kombinationen mit tramadol
ATE273697T1 (de) Pharmazeutische levothyroxinzubereitung
ATE366128T1 (de) Pharmazeutische zusammensetzung
DE59801987D1 (de) Pharmazeutische zusammensetzung enthaltend peptichemio
ATE251902T1 (de) Pharmazeutische zusammensetzung zur reduzierung der mcp-1 proteinsynthese
DE10081194D2 (de) Darreichungsform zur Applikation in Körperöffnungen
DE69907735D1 (de) Melatoninderivate und diese enthaltende pharmazeutische zubereitung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1059917

Country of ref document: EP

REN Ceased due to non-payment of the annual fee